Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Tianjin KingYork and Innovata Announce $190 Million Asthma JV

publication date: Jan 2, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tianjin KingYork Group Co. and Innovata HK Limited have formed a JV that will be located in Tianjin Economic-Technological Development Area (TEDA). The new company, which will be known as Tianjin Kinnovata Pharma, will produce powder inhalation drugs for asthma and COPD. The JV has been funded with $9.6 million initially. Over the longer term, the partners plan to invest $190 million in the project. The partners were advised by Morrison & Foerster, an international law firm specialized in life sciences, who also revealed that the JV expects to eventually attain revenues of more than 1 billion RMB ($160 million). More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...